|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Aastrom Biosciences Inc., of Ann Arbor, Mich., entered an agreement with Azienda Unita Sanitaria Locale di Ravenna, Oncologia Medica (AUSL) to purchase and use Aastrom's bone marrow stem cell therapy product for an experimental clinical approach in the treatment of breast cancer. AUSL will use the AastromReplicell System to generate bone marrow stem cells in the adjuvant treatment of high-risk breast cancer patients. The study is funded by the Italian government, and follows AUSL's recent purchase agreement for the AastromReplicell System platform and associated SC-I Therapy Kits.
Achillion Pharmaceuticals Inc., of New Haven, Conn., said it completed a Phase ...